RATIONALE & OBJECTIVE: Inflammation, cardiac remodeling, and fibrosis may explain in part the excess risk for cardiovascular disease (CVD) in patients with chronic kidney disease (CKD). Growth differentiation factor 15 (GDF-15), galectin 3 (Gal-3), and soluble ST2 (sST2) are possible biomarkers of these pathways in patients with CKD. STUDY DESIGN: Observational cohort study. SETTING & PARTICIPANTS: Individuals with CKD enrolled in either of 2 multicenter CKD cohort studies: the Seattle Kidney Study or C-PROBE (Clinical Phenotyping and Resource Biobank Study). EXPOSURES: Circulating GDF-15, Gal-3, and sST2 measured at baseline. OUTCOMES: Primary outcome was all-cause mortality. Secondary outcomes included hospitalization for physician-adjudicated heart failure and the atherosclerotic CVD events of myocardial infarction and cerebrovascular accident. ANALYTIC APPROACH: Cox proportional hazards models used to test the association of each biomarker with each outcome, adjusting for demographics, CVD risk factors, and kidney function. RESULTS: Among 883 participants, mean estimated glomerular filtration rate was 49±19mL/min/1.73m2. Higher GDF-15 (adjusted HR [aHR] per 1-SD higher, 1.87; 95% CI, 1.53-2.29), Gal-3 (aHR per 1-SD higher, 1.51; 95% CI, 1.36-1.78), and sST2 (aHR per 1-SD higher, 1.36; 95% CI, 1.17-1.58) concentrations were significantly associated with mortality. Only GDF-15 level was also associated with heart failure events (HR per 1-SD higher, 1.56; 95% CI, 1.12-2.16). There were no detectable associations between GDF-15, Gal-3, or sST2 concentrations and atherosclerotic CVD events. LIMITATIONS: Event rates for heart failure and atherosclerotic CVD were low. CONCLUSIONS: Adults with CKD and higher circulating GDF-15, Gal-3, and sST2 concentrations experienced greater mortality. Elevated GDF-15 concentration was also associated with an increased rate of heart failure. Further work is needed to elucidate the mechanisms linking these circulating biomarkers with CVD in patients with CKD.
RATIONALE & OBJECTIVE:Inflammation, cardiac remodeling, and fibrosis may explain in part the excess risk for cardiovascular disease (CVD) in patients with chronic kidney disease (CKD). Growth differentiation factor 15 (GDF-15), galectin 3 (Gal-3), and soluble ST2 (sST2) are possible biomarkers of these pathways in patients with CKD. STUDY DESIGN: Observational cohort study. SETTING & PARTICIPANTS: Individuals with CKD enrolled in either of 2 multicenter CKD cohort studies: the Seattle Kidney Study or C-PROBE (Clinical Phenotyping and Resource Biobank Study). EXPOSURES: Circulating GDF-15, Gal-3, and sST2 measured at baseline. OUTCOMES: Primary outcome was all-cause mortality. Secondary outcomes included hospitalization for physician-adjudicated heart failure and the atherosclerotic CVD events of myocardial infarction and cerebrovascular accident. ANALYTIC APPROACH: Cox proportional hazards models used to test the association of each biomarker with each outcome, adjusting for demographics, CVD risk factors, and kidney function. RESULTS: Among 883 participants, mean estimated glomerular filtration rate was 49±19mL/min/1.73m2. Higher GDF-15 (adjusted HR [aHR] per 1-SD higher, 1.87; 95% CI, 1.53-2.29), Gal-3 (aHR per 1-SD higher, 1.51; 95% CI, 1.36-1.78), and sST2 (aHR per 1-SD higher, 1.36; 95% CI, 1.17-1.58) concentrations were significantly associated with mortality. Only GDF-15 level was also associated with heart failure events (HR per 1-SD higher, 1.56; 95% CI, 1.12-2.16). There were no detectable associations between GDF-15, Gal-3, or sST2 concentrations and atherosclerotic CVD events. LIMITATIONS: Event rates for heart failure and atherosclerotic CVD were low. CONCLUSIONS: Adults with CKD and higher circulating GDF-15, Gal-3, and sST2 concentrations experienced greater mortality. Elevated GDF-15 concentration was also associated with an increased rate of heart failure. Further work is needed to elucidate the mechanisms linking these circulating biomarkers with CVD in patients with CKD.
Authors: Paula T Einhorn; Barry R Davis; Barry M Massie; William C Cushman; Linda B Piller; Lara M Simpson; Daniel Levy; Chuke E Nwachuku; Henry R Black Journal: Am Heart J Date: 2007-01 Impact factor: 4.749
Authors: Robin A P Weir; Ashley M Miller; Grace E J Murphy; Suzanne Clements; Tracey Steedman; John M C Connell; Iain B McInnes; Henry J Dargie; John J V McMurray Journal: J Am Coll Cardiol Date: 2010-01-19 Impact factor: 24.094
Authors: Giuseppe Maiolino; Giacomo Rossitto; Luigi Pedon; Maurizio Cesari; Anna Chiara Frigo; Matteo Azzolini; Mario Plebani; Gian Paolo Rossi Journal: Arterioscler Thromb Vasc Biol Date: 2015-01-22 Impact factor: 8.311
Authors: Casey M Rebholz; Elizabeth Selvin; Menglu Liang; Christie M Ballantyne; Ron C Hoogeveen; David Aguilar; John W McEvoy; Morgan E Grams; Josef Coresh Journal: Kidney Int Date: 2017-08-31 Impact factor: 10.612
Authors: Elisabet Zamora; Josep Lupón; Marta de Antonio; Amparo Galán; Mar Domingo; Agustín Urrutia; Maribel Troya; Antoni Bayes-Genis Journal: Int J Cardiol Date: 2014-10-11 Impact factor: 4.164
Authors: Tibor Kempf; Stephan von Haehling; Timo Peter; Tim Allhoff; Mariantonietta Cicoira; Wolfram Doehner; Piotr Ponikowski; Gerasimos S Filippatos; Piotr Rozentryt; Helmut Drexler; Stefan D Anker; Kai C Wollert Journal: J Am Coll Cardiol Date: 2007-08-24 Impact factor: 24.094
Authors: Kai C Wollert; Tibor Kempf; Bo Lagerqvist; Bertil Lindahl; Sylvia Olofsson; Tim Allhoff; Timo Peter; Agneta Siegbahn; Per Venge; Helmut Drexler; Lars Wallentin Journal: Circulation Date: 2007-09-11 Impact factor: 29.690
Authors: Rudolf A de Boer; Dirk J A Lok; Tiny Jaarsma; Peter van der Meer; Adriaan A Voors; Hans L Hillege; Dirk J van Veldhuisen Journal: Ann Med Date: 2010-12-28 Impact factor: 4.709
Authors: Alison C MacKinnon; Xiaojun Liu; Patrick Wf Hadoke; Mark R Miller; David E Newby; Tariq Sethi Journal: Glycobiology Date: 2013-02-19 Impact factor: 4.313
Authors: Manvir K Hayer; Ashwin Radhakrishnan; Anna M Price; Boyang Liu; Shanat Baig; Christopher J Weston; Luca Biasiolli; Charles J Ferro; Jonathan N Townend; Richard P Steeds; Nicola C Edwards Journal: JACC Cardiovasc Imaging Date: 2020-07-15
Authors: Lediya T Cheru; Kathleen V Fitch; Charles F Saylor; Michael Lu; Udo Hoffmann; Janet Lo; Steven K Grinspoon Journal: AIDS Date: 2019-02-01 Impact factor: 4.177
Authors: Flora Huang; Philip W Connelly; G V Ramesh Prasad; Michelle M Nash; Lakshman Gunaratnam; Djeven P Deva; Charmaine E Lok; Weiqiu Yuan; Rachel M Wald; Tamar Shalmon; Ron Wald; Kim A Connelly; Andrew T Yan Journal: J Nephrol Date: 2020-09-10 Impact factor: 3.902
Authors: Nisha Bansal; Leila R Zelnick; Christie M Ballantyne; Paulo H M Chaves; Robert H Christenson; Josef Coresh; Christopher R deFilippi; James A de Lemos; Lori B Daniels; Alan S Go; Jiang He; S Susan Hedayati; Kunihiro Matsushita; Vijay Nambi; Michael G Shlipak; Jonathan J Taliercio; Stephen L Seliger Journal: Am J Kidney Dis Date: 2021-07-19 Impact factor: 8.860
Authors: Alexander J Kula; Ronit Katz; Leila R Zelnick; Elsayed Soliman; Alan Go; Michael Shlipak; Rajat Deo; Bonnie Ky; Ian DeBoer; Amanda Anderson; Rob Christenson; Stephen L Seliger; Chris Defilippi; Harold I Feldman; Myles Wolf; John Kusek; Tariq Shafi; Jiang He; Nisha Bansal Journal: Nephrol Dial Transplant Date: 2021-12-02 Impact factor: 5.992